The UFD1L (Ubiquitin Fusion Degradation 1 Like) antibody is a research tool targeting the UFD1L protein, a critical component of the ubiquitin-proteasome system involved in protein quality control. UFD1L functions as a cofactor for the AAA-ATPase p97 (VCP), facilitating the degradation of misfolded or ubiquitinated proteins through the endoplasmic reticulum-associated degradation (ERAD) pathway. It plays roles in cell cycle regulation, DNA repair, and embryonic development. Notably, the UFD1L gene is located within the 22q11.2 chromosomal region, whose deletion is associated with DiGeorge syndrome, a congenital disorder characterized by cardiac, craniofacial, and immune abnormalities. Studies using UFD1L antibodies (often generated in rabbit or mouse hosts) aim to elucidate its expression patterns, subcellular localization, and molecular interactions via techniques like Western blotting, immunohistochemistry, and immunofluorescence. Research has also explored its potential involvement in cancer progression and neurodevelopmental disorders. Commercial UFD1L antibodies are typically validated for specificity and affinity, with applications spanning basic molecular biology to disease mechanism studies. Understanding UFD1L's functions contributes to insights into cellular proteostasis and developmental pathologies.